Dr. Timothy Edward Kubal, MD

Dr. Kubal practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Kubal's NPI, 1982808689, was assigned on June 14, 2007. Dr. Kubal graduated from Florida State University College Of Medicine in 2007. Dr. Kubal holds Florida license ME106683.

Dr. Kubal's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Kubal also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Kubal's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Kubal to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kubal practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kubal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kubal is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Kubal's licenses on file in 2 states: Florida and North Carolina.

Dmand AI lists chronic anemia, chronic embolism thrombosis, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and purpura and thrombocytopenia among the conditions Dr. Kubal treats.

CMS data shows 270 Medicare services from Dr. Kubal across 3 procedure codes in 2024, all of them office visits, for 114 Medicare patients. Medicare paid $23,612 for them.

CMS counts 114 Medicare patients who saw Dr. Kubal in 2024. The largest group is 65 to 74, with 46 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kubal's median patient age at 64, with 63% women.

In 2024, Dr. Kubal wrote 569 Medicare Part D claims for 97 patients. 62% of them were for generic drugs. CMS names the drug for 293 of them, across 13 drugs with 11 or more claims each, at $2,999,550 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Kubal for performance year 2024, reported as part of a group. Dr. Kubal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kubal as offering telehealth.

Dmand AI links 24 papers to Dr. Kubal, published from 2011 to 2025. 2020 was the busiest year, with 5. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Critical Pathways. Dr. Kubal has published most often in J Natl Compr Canc Netw. Dr. Kubal's most frequent co-authors are Jeffrey E. Lancet, MD, Lawrence Nathan Shulman, MD and Saundra S. Buys, MD.

Dmand AI links Dr. Kubal to 4 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases and Leukemia, Neutrophilic, Chronic. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 4.

CMS Open Payments shows 19 general payments to Dr. Kubal from 5 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 84% of the total. Sanofi and Genzyme US Companies paid the most, $13,720.

Dr. Kubal graduated from Florida State University College Of Medicine in 2007.

Dr. Kubal is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.